Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

Blood (2012) 119 (19): 4383–4386.

https://doi.org/10.1182/blood-2010-12-327072

Published: 2012

Includes: Supplemental data

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

Friederike Schneider, Annika Dufour, Tobias Benthaus, Stephanie Schneider, Gudrun Mellert, Evelyn Zellmeier, Stefan K Bohlander, Michael Unterhalt, Michaela Feuring-Buske, Christian Buske, Jan Braess, Maria Cristina Sauerland, Achim Heinecke, Wolfgang Berdel, Thomas Buechner, Bernhard Wörmann, Wolfgang Hiddemann, Karsten Spiekermann, Eva Hoster

Blood (2009) 114 (22): 2635.

https://doi.org/10.1182/blood.V114.22.2635.2635

Published: 2009

Journal Articles

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Blood (2009) 113 (21): 5250–5253.

https://doi.org/10.1182/blood-2008-09-172668

Published: 2009

Includes: Supplemental data

Journal Articles

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske, Jan Braess, Achim Heinecke, Maria C. Sauerland, Wolfgang E. Berdel, Thomas Buechner, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2008) 112 (11): 2531.

https://doi.org/10.1182/blood.V112.11.2531.2531

Published: 2008

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

A Rapid and Sensitive Method for Large-Scale Screening of CEBPA Mutations in AML Patients with Normal Karyotype.

Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Wolfgang Hiddemann, Karsten Spiekermann, Annika Dufour

Blood (2007) 110 (11): 3483.

https://doi.org/10.1182/blood.V110.11.3483.3483

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential

Sridhar Vempati, Carola Reindl, Seshu Kumar Kaza, Ruth Kern, Theodora Malamoussi, Martin Dugas, Gudrun Mellert, Susanne Schnittger, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2007) 110 (2): 686–694.

https://doi.org/10.1182/blood-2006-10-053181

Published: 2007

Journal Articles

Oncogenic CBL Mutants Have Transforming Potential in Cells Expressing the FLT3 Tyrosine Kinase.

Carola Reindl, Sridhar Vempati, Hilmar Quentmeier, Gudrun Mellert, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2006) 108 (11): 1446.

https://doi.org/10.1182/blood.V108.11.1446.1446

Published: 2006

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

Journal Articles

Arginine (R) at Position 595 in FLT3 Is Critical for Transforming Potential of FLT3-Length Mutations.

Sridhar Vempati, MSc, Ruth Schwab, Theodora Malamoussi, Martin Dugas, MD, Gudrun Mellert, Susanne Schnittger, PhD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD

Blood (2005) 106 (11): 1598.

https://doi.org/10.1182/blood.V106.11.1598.1598

Published: 2005

Journal Articles

Applicability of FLT3-Length Mutations in Exon 14 as a Follow up Marker in AML: An Experience of 148 Cases and 517 Follow up Samples Using Conventional and Real Time PCR.

Susanne Schnittger, PhD, Wolfgang Kern, MD, Gudrun Mellert, Wolfgang Hiddemann, MD, Claudia Schoch, MD, Torsten Haferlach, MD

Blood (2004) 104 (11): 2014.

https://doi.org/10.1182/blood.V104.11.2014.2014

Published: 2004

NARROW

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

A Rapid and Sensitive Method for Large-Scale Screening of CEBPA Mutations in AML Patients with Normal Karyotype.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential

Oncogenic CBL Mutants Have Transforming Potential in Cells Expressing the FLT3 Tyrosine Kinase.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Arginine (R) at Position 595 in FLT3 Is Critical for Transforming Potential of FLT3-Length Mutations.

Applicability of FLT3-Length Mutations in Exon 14 as a Follow up Marker in AML: An Experience of 148 Cases and 517 Follow up Samples Using Conventional and Real Time PCR.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only